Moderna Inc stock: Phase 3 melanoma data sharpen oncology outlook

Moderna Inc stock is in focus after detailed Phase 3 data for the company's personalized melanoma vaccine were presented at the ESMO 2026 oncology congress and formally published alongside the presentation. Moderna said on October 24 that intismeran autogene, also known as V940 or mRNA-4157, is being developed with Merck.

At Lang & Schwarz, the stock was quoted at 197.39 euros on October 29, 2026, at 17:09:25 Berlin time. The current quote is valid and dated, but a verified Xetra close for the same session was not available for this report, so no Xetra day comparison is stated.

What the melanoma data add

The INTerpath-001 trial evaluated intismeran plus pembrolizumab, Merck's Keytruda, against Keytruda alone in patients with completely resected stage IIB-IV melanoma. After a median follow-up of 24.6 months, the combination reduced the risk of recurrence or death by 42 percent, with a hazard ratio of 0.58 and a p-value below 0.001.

The company also reported a stronger effect after the six-month immunization period in a prespecified sensitivity analysis. In that analysis, the reduction in recurrence or death was 58 percent. Moderna said the individualized treatment was successfully manufactured for more than 99 percent of randomized patients, an operational detail that is relevant to the commercial potential of a patient-specific therapy.

Safety remains part of the investment assessment. Grade 3 to 5 treatment-related adverse events occurred in 14.2 percent of patients receiving the combination and in 13.4 percent of those receiving Keytruda alone. The therapy remains investigational and potential approval is not guaranteed.

Course change since the prior report

The current Lang-&-Schwarz quote is 12.12 percent above the 176.05-euro quote recorded in the most recent relevant own report on October 27. This is a separate comparison with that earlier report, not a Xetra day performance measure. The real-time quote of Moderna Inc stock remains the relevant live reference for subsequent trading.

Investing.com reported on October 29 that the formal publication of the Phase 3 data and the ESMO presentation helped shift attention back to the clinical merits of the program. The next scheduled company-specific checkpoint is Moderna's third-quarter report on November 6.

The broader market context is available through current S&P 500 market reports.

More news and analyses on Moderna Inc stock.